HALOZYME THERAPEUTICS INC (HALO)
US40637H1095 - Common Stock
| TTM (2023-9-30) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | 2019 (2019-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| CASH FLOWS FROM OPERATING ACTIVITIES | ||||||||
| Net Income | 253.90M | 202.10M | 402.70M | 129.10M | -72.20M | |||
| Depreciation Amortization | 71.30M | 49.60M | 3.00M | 3.30M | 4.10M | |||
| Income Taxes - Deferred | 39.80M | 40.00M | -155.40M | N/A | N/A | |||
| Change In Working Capital | -17.70M | -86.00M | 3.70M | -103.70M | -50.50M | |||
| Interest Paid | N/A | 6.10M | 3.30M | 6.50M | 9.00M | |||
| Taxes Paid | N/A | 16.20M | -400.00K | 200.00K | 200.00K | |||
| Other non cash items | 21.40M | 34.30M | 45.40M | 26.80M | 33.30M | |||
| OPERATING CASH FLOW | 368.60M | 240.10M | 299.40M | 55.50M | -85.40M | |||
| CASH FLOWS FROM INVESTING ACTIVITIES | ||||||||
| Capital Expenditure | -15.00M | -4.80M | -1.50M | -2.50M | -4.00M | |||
| Other Investing Activity | -75.30M | -482.20M | -404.80M | 80.90M | -1.50M | |||
| INVESTING CASH FLOW | -90.30M | -487.00M | -406.30M | 78.40M | -5.50M | |||
| CASH FLOWS FROM FINANCING ACTIVITIES | ||||||||
| Debt Issued/Reduced | -13.50M | 624.50M | 415.80M | -19.60M | 339.30M | |||
| Stock Issued/Repurchased | -137.70M | -186.00M | -337.50M | -86.70M | -185.80M | |||
| Other Financing Activity | N/A | -76.20M | -400.00K | 0.00 | -300.00K | |||
| FINANCING CASH FLOW | -151.70M | 362.40M | 77.90M | -106.30M | 153.20M | |||
| CHANGE IN CASH | 126.60M | 115.50M | -29.00M | 27.60M | 62.30M | |||
| FREE CASH FLOW | ||||||||
| Operating Cash Flow | 368.60M | 240.10M | 299.40M | 55.50M | -85.40M | |||
| Capital Expenditure | -15.00M | -4.80M | -1.50M | -2.50M | -4.00M | |||
| FREE CASH FLOW | 353.60M | 235.30M | 297.90M | 53.00M | -89.40M | |||
All data in USD